Evoworks Bio
Revolutionizing the hardware of bioproduction
Introduction
Pharmaceuticals have been transferred by the arrival of biologics, with treatments like GLP-1s and mRNA changing the landscape of what's possible in medicine, bioproduction methods are becoming increasingly critical.
Evoworks has a revolutionary approach to reduce late stage failures and cost of scale, combining a focus on user needs and go-to-market strategy to disrupt the biomanufacturing industry and enable more novel biologics to reach patients in need.
Problem
Before a drug in the lab can be brought to clinical trials there’s a 16-month period of process development and manufacturing. The transition to full production scale is expensive : 200 million dollars per approved drug. And it’s risky; Regeneron’s Covid-19 treatment, which was proven effective as early as September 2020 never saw widespread distribution due to manufacturing constraints.
We assert that this is not a universal limitation, it is a flaw in the current design of bioreactors. Bioreactors were borrowed from Chemical Engineers back in the 50’s and have never been purpose-built for pharmaceutical pipelines. The conditions for cells are fundamentally changed from discovery in a lab to the large bioreactors of production. Oxygen, temperature, shear forces and nurient gradients all make the environment at scale uninviting to the biologics, so what works in the lab doesn't survive at scale.
Opportunity
Evoworks Bio is a team of lifetime scalability and automation engineers who truly love this field. This is our jam. And by borrowing heuristics from big tech infrastructure, we have a novel biomanufacturing platform that reduces each of these barriers: time, cost, and risk by a factor of 10 with an annualized value add of over $100 billion.
Where others try to predict failures more accurately or make incremental improvements to the existing systems, our technology puts the biologics in conditions identical to the lab, providing predictable, immediate, on-the-fly scalability to massively improve the value proposition of all novel biologics.
Our technology is a modular, scale-out approach to bioreactors which maintains the conditions for bioproduction exactly as they are in the lab at any scale. Our provisional patent covers a system where the consumables cost, manufacture and process design are all considered to enable immediate scale up with no biological risk.